Literature DB >> 34295069

A Prospective Study Comparing the Role of 18 FDG PET-CT with Contrast-Enhanced Computed Tomography and Tc99m Bone Scan for Staging Locally Advanced Breast Cancer.

Sandeep Bhoriwal1, S V S Deo1, Rakesh Kumar2, Sanjay Thulkar3, Ajay Gogia4, D N Sharma5, Sandeep Mathur6.   

Abstract

Locally advanced breast cancer (LABC) patients require an accurate staging of the disease to rule out distant metastases. Various imaging investigations are used to stage LABC patients. The present study is a prospective comparison of conventional imaging (CI) with fusion positron-emission tomography and computed tomography (PET-CT) scans in the staging of LABC patients. Seventy-three consecutive LABC patients presenting to the breast cancer clinic of the tertiary care cancer institute were included in the study. All patients underwent contrast-enhanced computed tomography, Tv99m bone scintigraphy, and fusion PET-CT. Histology of the metastatic site was confirmed wherever possible. The disparity between the two imaging findings was compared. Doubtful lesions were observed clinically for at least 2 years to confirm their nature. PET-CT detected a higher number of lymph nodes in the axilla, internal mammary, and supraclavicular region as compared to CI. PET-CT upstaged 36.98% and downstaged 5.4% of the patients respectively leading to a change in the management in 30.13% of the patients. Sensitivity, specificity, positive predictive value, and negative predictive value of CI and PET-CT were 71.87%, 87.80%, 82.14%, and 80%, and 90.90%, 90%, 88.23%, and 92.30% respectively. PET-CT was more accurate in staging the LABC patients as compared to CI. PET-CT is more accurate then contrast-enhanced CT and bone scintigraphy for staging locally advanced breast carcinoma patients. It can replace multiple organ-directed imaging in staging breast cancer. It can provide accurate staging of the disease so that patients can be prognosticated and can be directed to the most appropriate treatment plans. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Breast cancer; Cancer staging; Positron-emission tomography-computed tomography

Year:  2021        PMID: 34295069      PMCID: PMC8272774          DOI: 10.1007/s13193-021-01299-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  26 in total

Review 1.  A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases.

Authors:  Carmen R Isasi; Renee M Moadel; M Donald Blaufox
Journal:  Breast Cancer Res Treat       Date:  2005-03       Impact factor: 4.872

2.  The role of FDG-PET/CT in suspected recurrence of breast cancer.

Authors:  Lea Radan; Simona Ben-Haim; Rachel Bar-Shalom; Luda Guralnik; Ora Israel
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

3.  Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.

Authors:  T S Kim; W K Moon; D S Lee; J K Chung; M C Lee; Y K Youn; S K Oh; K J Choe; D Y Noh
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

4.  Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective.

Authors:  C S Yap; M A Seltzer; C Schiepers; S S Gambhir; J Rao; M E Phelps; P E Valk; J Czernin
Journal:  J Nucl Med       Date:  2001-09       Impact factor: 10.057

5.  Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.

Authors:  D H Moon; J Maddahi; D H Silverman; J A Glaspy; M E Phelps; C K Hoh
Journal:  J Nucl Med       Date:  1998-03       Impact factor: 10.057

6.  Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Authors:  S Mahner; S Schirrmacher; W Brenner; L Jenicke; C R Habermann; N Avril; J Dose-Schwarz
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

7.  Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.

Authors:  Richard L Wahl; Barry A Siegel; R Edward Coleman; Constantine G Gatsonis
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

8.  Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread.

Authors:  Bernd Gerber; Eva Seitz; Heiner Müller; Annette Krause; Toralf Reimer; Günther Kundt; Klaus Friese
Journal:  Breast Cancer Res Treat       Date:  2003-11       Impact factor: 4.872

9.  Staging procedures in primary breast cancer.

Authors:  Daniela Müller; Günter Köhler; Ralf Ohlinger
Journal:  Anticancer Res       Date:  2008 Jul-Aug       Impact factor: 2.480

Review 10.  FDG PET, PET/CT, and breast cancer imaging.

Authors:  Eric L Rosen; William B Eubank; David A Mankoff
Journal:  Radiographics       Date:  2007-10       Impact factor: 5.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.